Loading
GU oncologist who led TALAPRO-2 and other trials combining PARP inhibitors with hormone therapy.
Neeraj Agarwal is SWOG Executive Officer for Genitourinary and Early Therapeutics and Professor of Medicine at the Huntsman Cancer Institute, University of Utah. A medical oncologist specialising in prostate and kidney cancer and targeted therapy, he was principal investigator of TALAPRO-2, the trial of talazoparib plus enzalutamide, and of CONTACT-03. His papers report the TALAPRO-2 randomised, placebo-controlled phase 3 trial in first-line metastatic castration-resistant prostate cancer in the Lancet and the design of CONTACT-02, a phase III study of cabozantinib plus atezolizumab versus a second novel hormone therapy in the same disease. He directs genitourinary oncology at Huntsman and works on PARP and the androgen receptor in prostate and renal cell carcinoma.
Shares SWOG Cancer Research Network, Renal cell carcinoma, Prostate cancer.
Shares TALAPRO-2, Talazoparib, PARP, Prostate cancer.
Shares CONTACT-03, Renal cell carcinoma.
Shares CONTACT-03, Renal cell carcinoma.
Shares TALAPRO-2, Prostate cancer.
Shares PARP, Androgen receptor, Prostate cancer.
Shares PARP, Androgen receptor, Prostate cancer.
Shares Androgen receptor, Prostate cancer.